Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 21445358
Mima A, et al. (2011) Activation of Src mediates PDGF-induced Smad1 phosphorylation and contributes to the progression of glomerulosclerosis in glomerulonephritis. PLoS One 6, e17929 21445358
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S466-p - SMAD1 (rat)
Modsite: sPHNPISsVs_____ SwissProt Entrez-Gene
Orthologous residues
SMAD1 (human): S463‑p, SMAD1 (mouse): S463‑p, SMAD1 (rat): S466‑p
Characterization
Methods used to characterize site in vivo immunoassay, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  mesangial-kidney
Cellular systems studied:  tissue
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PP2 decrease
siRNA PDGF inhibit treatment-induced increase c-Src siRNA
PDGF increase
PP2 PDGF inhibit treatment-induced increase
anti-TGFB1 PDGF no effect upon treatment-induced increase
PDGF LRP1 (rat) inhibit treatment-induced increase LRP1 siRNA augments treatment
angiotensin_2 increase
anti-PDGFR angiotensin_2 inhibit treatment-induced increase

S468-p - SMAD1 (rat)
Modsite: HNPISsVs_______ SwissProt Entrez-Gene
Orthologous residues
SMAD1 (human): S465‑p, SMAD1 (mouse): S465‑p, SMAD1 (rat): S468‑p
Characterization
Methods used to characterize site in vivo immunoassay, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  mesangial-kidney
Cellular systems studied:  tissue
Species studied:  rat
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Src (rat) transfection of dominant-negative enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, phospho-antibody, transfection of constitutively active enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PP2 decrease
siRNA PDGF inhibit treatment-induced increase c-Src siRNA
PDGF increase
PP2 PDGF inhibit treatment-induced increase
anti-TGFB1 PDGF no effect upon treatment-induced increase
PDGF LRP1 (rat) inhibit treatment-induced increase LRP1 siRNA augments treatment
angiotensin_2 increase
anti-PDGFR angiotensin_2 inhibit treatment-induced increase

Y419-p - Src (rat)
Modsite: RLIEDNEyTARQGAk SwissProt Entrez-Gene
Orthologous residues
Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
Methods used to characterize site in vivo immunoassay, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  mesangial-kidney
Cellular systems studied:  tissue
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PDGF increase
PP2 PDGF inhibit treatment-induced increase
PP2 decrease
anti-TGFB1 PDGF no effect upon treatment-induced increase
PDGF LRP1 (rat) inhibit treatment-induced increase LRP1 siRNA augments treatment
angiotensin_2 increase
anti-PDGFR angiotensin_2 inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  phosphorylation
Effect of modification (process):  cell growth, induced, signaling pathway regulation
Comments:  induces phosphorylation of SMAD, Src/SMAD1 signaling pathway